Kinase drug discovery 20 years after imatinib: progress and future directions
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
[HTML][HTML] Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …
considerable potential to improve clinical outcomes across multiple cancer types, including …
Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors
Despite advances in screening and therapeutics cancer continues to be one of the major
causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely …
causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely …
[HTML][HTML] Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …
World Health Organization (WHO) provides the foundation for therapeutic advances by …
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
CE McCoach, CM Blakely, KC Banks, B Levy… - Clinical Cancer …, 2018 - AACR
Purpose: Patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor
anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors …
anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors …
Liquid biopsy in non-small cell lung cancer: highlights and challenges
Non-small cell lung cancer is one leading cause of death worldwide, and patients would
greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged …
greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged …
Targeting ALK rearrangements in NSCLC: current state of the art
L Peng, L Zhu, Y Sun, J Stebbing, G Selvaggi… - Frontiers in …, 2022 - frontiersin.org
Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …
The role of circulating biomarkers in lung cancer
Lung cancer is the leading cause of cancer morbidity and mortality worldwide and early
diagnosis is crucial for the management and treatment of this disease. Non-invasive means …
diagnosis is crucial for the management and treatment of this disease. Non-invasive means …
Therapeutic Sequencing in ALK+ NSCLC
M Elsayed, P Christopoulos - Pharmaceuticals, 2021 - mdpi.com
Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a
model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher …
model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher …
[HTML][HTML] Targeting KRAS-mutant non–small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations
TF Burns, H Borghaei, SS Ramalingam… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Lung cancer represents 11.6% of all cancers globally, with more than 2 million new cases
worldwide in 2018. 1 Across all disease stages, non–small-cell lung cancer (NSCLC) has an …
worldwide in 2018. 1 Across all disease stages, non–small-cell lung cancer (NSCLC) has an …